Key Drivers
- Strong Cash Flow
- Healthy Liquidity
- Rich Valuation
AIAI Summary
PGNY now looks like a self-funding healthcare cash compounder rather than a speculative grower, but with the stock already priced at a fair premium, the key investment test is whether the 2027 selling season and utilization trends can sustain enough growth to justify valuation and reclaim the $27.85–$31.5 resistance zone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Healthy Liquidity
- •Rich Valuation
PGNY generates strong cash flow and remains financially stable, but modest margins and a premium valuation suggest limited near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Weak rebound
- •Overhead resistance
PGNY remains in a short-term downtrend, with sellers dominating over the last month; the bounce from $25.42 is only tentative unless it reclaims $27.85, with $25.4-$25.5 the key support.
Sharp selloff followed by a bounce from $25.42 to $26.28 suggests short-term demand but not a confirmed reversal
Sentiment & News
Key News Insights:
- •Record quarter
- •2027 visibility
- •Share volatility
Progyny delivered a record Q2 earnings beat and stronger 2027 visibility, but shares remained volatile despite the upbeat operating backdrop.
The results are fundamentally supportive for PGNY, though the stock may stay choppy near term as investors reassess the post-earnings move
Similar Companies in Healthcare
Other companies in the same sector with AI ratings